A FARID, ALYAAA EISSA, RWANM NADA, AHMEDM ELAMIR, MONAM. ELAMIR, AZZA2020-02-032020-02-032019Bae, SC, Koh, HK, Chang, D, Kim, M, Park, J, et al, 2000: Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 10, 6:405-9. Bombardier, C, Gladman, DD, Urowitz, MB, Caron, D, Chang, CH, 1992: Derivation of the SLEDAI: A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 35:630-40. Bruns, A, Blass, S, Hausdorf, G, Burmester, GR, Hiepe, F, 2000: Nucleosomes are major T and B cell autoantigens in the systemic lupus erythematosus. Arthritis Rheumat. 43: 2307-15. Casali, P, Schettino, EW, 1996: Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210:167-79 Ceppellini, P, Polli, E, Celada, F, 1957: A DNA-reacting factor in serum of a patient with lupus erythematous diffusus. Proceed. Soc. Exp. Biol. Med. 96:572-4. Chu, P, Pendry, K, Blecher, TE, 1988: Detection of lupus anticoagulant in patients’ attending an anticoagulation clinic. Brit. Med. J. 297: 1449-53 Cozzani, E, Drosera, M, Gasparini, G, Parodi, A, 2014: The serology of lupus erythematosus: Correlation between immunopathological features and clinical aspects. Autoimm. Dis. 4:1-13. Egner, W, 2000: The use of laboratory tests in diagnosis of SLE. J. Clin. Pathol. 53, 6:424-32 Elkon, K, Casali, P, 2008: Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 4, 9: 491-8. Grygiel-Górniak, B, Rogacka, N, Puszczewi cz, M, 2018: Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications. Reumatol. 56, 4:243-8. Hamdy, S, Gamal, T. Khalil, AK, Ibrahim, NI, 2010: Pattern of systemic lupus erythematosus in Egyptian patients: the impact of disease activity on the quality of life. Pan Afr. Med. J. 6:14-20. Mechanisms of autoantibody production in systemic lupus erythematosus. Front Immunol. 6:22-8. Hargraves, M, Richmond, H, Morton, R, 1948: Presentation of two bone marrow components, the tart cell and the LE cell. Mayo Clin. Proceed. 21:25-8. Hochberg, MC, 1997: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40:1725 Kurien, BT, Scofield, RH, 2006: Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand. J. Immunol. 64: 227-35. Müller, MM, Muir, TW, 2014: Histones: At the crossroads of peptide and protein chemistry. Chem. Rev. 115, 6: 2296-349. Nagai, T, Arinuma, Y, Yanagida, T, Yamamoto, K, Hirohata, S, 2005: Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum. 52, 3:847-55. Perrin, LH, Lambert, PH, Nydegger, UE, Miescher, PA, 1973: Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level. N. Engl. J. Med. 2:16-27. Sherer, Y, Gorstein, A, Fritzler, MJ, Shoenfeld, Y, 2004: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34: 501-37. Stoll, TS, Stucki, G, Malik, J, 1996: Further validation of the BILAG disease activity index in patients with SLE. Ann. Rheum. Dis. 55, 10:756-60. Tan, EM, Kunkel, HG, 1966: Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J. Immunol. 96:464-71. van der Vlag, J, Berden, JHM, 2011: Lupus nephritis: Role of anti-nucleosome antibodies. Semin. Nephrol. 31:376-89. Walport, MJ, 2002: Complement and systemic lupus erythematosus. Arthritis Res. 4: S279-93. Walravens, M, 1987: Systemic diseases and the detection of nuclear and anticytoplasmic antibodies: A historical review. Clin. Rheumatol. 6:9-17.https://t.ly/xBp7bMSA Google ScholarSystemic lupus erythematosus (SLE) is a prototypic multisystem autoimmune disease with a vast spectrum of clinical presentations including almost all body organs and tissues. The incidence of lupus has tripled in the last 40 years, mainly due to the improved diagnosis. For more than 60 years the presence of autoantibodies in patients with SLE has been known. A great effort is being made for understanding the diagnostic, pathogenic and prognostic meaning of these autoantibodies. The study demonstrated the significance of autoantibodies test in Egyptian SLE patients. The results showed that 93.3% of patients have positive ANA test, 90% have positive anti-dsDNA. Anti-Sm antibodies were in 40% and 49.3% of patients have positive anti-nucleosome antibody test. Also, 30.6% of patients deve-loped a positive anti-histone test & 26% have positive anti-ribosomal test. Anti-phospholipids antibodies were found in 44.6% of patients. Levels of C3 & C4 (0.552±0.43 & 0.125±0.12, respectively) were lower than that of control group (1.2±0.35 & 0.42±0.54 for C3 & C4, respectively). Key words: Egypt, Systemic lupus erythematosus, Autoantibodies testenEgyptSystemic lupus erythematosusAutoantibodies testArticle